- Advertisement -Newspaper WordPress Theme
The Stock MarketFedEx, Sarepta Therapeutics and more

FedEx, Sarepta Therapeutics and more

Engineers transfer a 350-volt battery pack to be put in in a Fedex Corp. Express General Motors Co. (GM) van on the VIA Motors Inc. facility in Orem, Utah, U.S. on Monday, Feb. 17, 2014.

George Frey | Bloomberg | Getty Images

Here are the shares making headlines after the bell.

FedEx — Shares of the delivery firm rose more than 3% after FedEx issued upbeat steerage for its full fiscal 12 months, projecting an increase in adjusted earnings. FedEx reported blended outcomes for its not too long ago accomplished fiscal fourth quarter, with $6.87 in adjusted earnings per share on $24.39 billion of income. Analysts surveyed by Refinitiv have been anticipating $6.86 in earnings per share on $24.56 billion of income.

Sarepta Therapeutics — The biopharma inventory dropped more than 5% in prolonged buying and selling after the FDA positioned a medical maintain on Sarepta’s therapy for Duchenne muscular dystrophy. Sarepta stated there was a “serious adverse event” in one of many research for the therapy.

Smith & Wesson Brands — Shares of the firearms producer dipped about 2% after Smith & Wesson’s fiscal fourth-quarter report confirmed a 12 months over 12 months decline in income and gross margin. The firm, which has a market cap of roughly $650 million, hiked its quarterly divided to 10 cents per share from 8 cents.


Please enter your comment!
Please enter your name here

Exclusive content

- Advertisement -Newspaper WordPress Theme

Latest article

More article

- Advertisement -Newspaper WordPress Theme